Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
James Scibetta
AddedFeb 15, 2024
UpdatedMay 31, 2026
James Scibetta

James Scibetta

Board Member, Matinas Biopharma Holdings

CrunchbaseLinkedInThe Org

James Scibetta's Career

Matinas Biopharma Holdings
Matinas Biopharma Holdings

Bedminster, NJ, US

Board Member· Board
Aquestive Therapeutics
Aquestive Therapeutics

Warren Township, NJ, US

Board Member· Board
ImmuneID
ImmuneID

Boston, MA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

James Scibetta's Career

Matinas Biopharma Holdings
Matinas Biopharma Holdings
Public342013Bedminster, NJ, US
Board Member· Board

Leadership at Matinas Biopharma Holdings

Jerome D. JabbourJerome D. JabbourBoard Member
Mr. Herbert Conrad J.Mr. Herbert Conrad J.Board Member

Similar to Matinas Biopharma Holdings

MatriSys BioscienceMatriSys BioscienceLos Angeles, CA, USBiopharmaceuticalsest. 2015MatriSys BioscienceLos Angeles, CA, US · est. 2015

MatriSys Bioscience: A US-based biopharmaceutical company specializing in rational microbiome therapies.

Seed · $4.5M8
Mana.bioMana.bioTel Aviv, Tel Aviv District, ILDrug Delivery, Therapeuticsest. 2021Mana.bioTel Aviv, Tel Aviv District, IL · est. 2021

Mana.bio: An AI-driven startup specializing in LNP development for mRNA-based therapies and vaccines.

Seed · $29.5M
PharmaINPharmaINBothell, WA, USDrug Deliveryest. 2001PharmaINBothell, WA, US · est. 2001

PharmaIN, a US-based biopharmaceutical firm, enhances injectable therapeutics via patented PGC™ technology.

Seed · $1.5M18
Metis TherapeuticsMetis TherapeuticsCambridge, MA, USDrug Developmentest. 2017Metis TherapeuticsCambridge, MA, US · est. 2017

METiS Therapeutics: Developing small molecule drugs for diverse illnesses through integrated discovery.

Series B · $261M36
Aquestive Therapeutics
Aquestive Therapeutics
Public$293.1M1302004Warren Township, NJ, US
Board Member· Board

Leadership at Aquestive Therapeutics

Marco TagliettiMarco TagliettiBoard Member
Julie KropJulie KropBoard Member
Tim MorrisTim MorrisBoard Member
Santo J. CostaSanto J. CostaBoard Member
Dan BarberDan BarberCEO
Greg BrownGreg BrownBoard Member

Similar to Aquestive Therapeutics

Axsome TherapeuticsAxsome TherapeuticsNew York City, NY, USTherapeuticsest. 2012Axsome TherapeuticsNew York City, NY, US · est. 2012

American biopharmaceutical firm, Axsome Therapeutics, develops therapies for pain and neurological disorders globally.

Public · $432M383
Assertio HoldingsAssertio HoldingsNewark, CA, USPharmaceuticalsest. 2020Assertio HoldingsNewark, CA, US · est. 2020

Innovative Newark-based pharmaceutical company developing orphan drugs and therapeutic solutions for US patients.

Public · $1B42
Supernus PharmaceuticalsSupernus PharmaceuticalsRockville, MD, USPharmaceuticalsest. 2005Supernus PharmaceuticalsRockville, MD, US · est. 2005

US-based Supernus Pharmaceuticals develops and markets proprietary drugs for central nervous system disorders.

Public · $689.5M612
ImmuneID
ImmuneID
Series A$67M482020Boston, MA, US
CEO· C-Suite · Management

Leadership at ImmuneID

Lea HachigianLea HachigianCo-Founder
Pam StetkiewiczPam StetkiewiczBoard Member
Tomasz KulaTomasz KulaBoard Member
Christoph WestphalChristoph WestphalBoard Member
Ittai HarelIttai HarelBoard Member

James Scibetta's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to James Scibetta

Ben ZeskindBen ZeskindBoard Member · ImmuneeringAlan JoslynAlan JoslynBoard Member · Synergy PharmaceuticalsNoam SolomonNoam SolomonCo-Founder · ImmunaiSamedy OukSamedy OukCo-Founder · ImmuneTargetAmanda WagnerAmanda WagnerCEO · Immunitas Therapeutics